LogicBio Therapeutics, Inc. (LOGC) Social Stream
LogicBio Therapeutics Inc (LOGC) Price Targets From Analysts
Use the tables below to see what analysts covering LogicBio Therapeutics Inc think about its future price and what recommendations they have for investors and traders.
|Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
The Trend in the Analyst Price Target
LOGC's average price target has moved down $7.13 over the prior 51 weeks.
LOGC reports an average of 280.33% for its upside potential over the past 19 months.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
LOGC Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The Trend in the Broker Recommendations
Over the past 61 days, LOGC's average broker recommendation rating improved by 0.67.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- LOGC has a higher upside potential (average analyst target price relative to current price) than 492.87% of all US stocks.
- The average analyst price target of LOGC is higher than 98.14% of all US stocks.
- The number of analysts covering the stock of LOGC is greater than 300.96% of stocks in the small market cap category.
- LOGC has a less variance in analysts' estimates than -182.4% of all US stocks.
In the Pharmaceutical Products industry, SIOX, BCEL and SEEL are the three stocks most similar to LogicBio Therapeutics Inc regarding the price target and analyst recommendation information presented here.
Make investment decisions regarding LOGC using the data that counts. Try POWR Ratings for free.